THE US Food and Drug Administration (FDA) has approved Zulresso (brexanolone) injection for intravenous (IV) use for the treatment of postpartum depression (PPD) in adult women.
This is the first drug approved by the FDA specifically for the serious condition of PPD, which can be a major depressive syndrome with thoughts about harming self or the infant and can interfere with the maternal-infant bond.
As yet brexanolone has not been approved for marketing in Australia.
The above article was sent to subscribers in Pharmacy Daily's issue from 22 Mar 19
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 22 Mar 19
